SynAbs recent antibody innovations

New primary monoclonal antibodies · 13. May 2025

Decoding MRSA: Monoclonal Antibody Innovation Targeting PBP2a and PBP2b

SYnAbs innovative mouse and rat RUO monoclonals to detect MRSA strains targeting PBP2a and PBP2b for diagnosis in lateral flow immunoassay

New primary monoclonal antibodies · 06. May 2025

Tackling Colistin Resistance: Monoclonal Antibody Strategies Against MCR-1

MCR-1-mediated colistin resistance detection using SYnAbs monoclonal antibodies

New primary monoclonal antibodies · 29. April 2025

Advancing Vancomycin B Resistance Detection: A Monoclonal Antibody Approach

SYnAbs unique primary monoclonal antibody to specifically detect vancomycin B (vanB) to tackle the threat of antibiotic resistance

New primary monoclonal antibodies · 23. April 2025

Targeting Estradiol with R&D-Grade Monoclonal Antibodies: Unlocking the Potential of Steroid Hormone Research

SYnAbs RUO monoclonal antibodies of mouse and rat species highly specific to Estradiol without cross-reactivity to close steroid analogs

New primary monoclonal antibodies · 22. April 2025

Tackling Antibiotic Resistance: Detection of Vancomycin A with Monoclonal Antibodies

SYnAbs unique specific monoclonal antibodies for the detection of Vancomycin A without cross-reactivity to Vancomycin B or close analogs for antibiotic resistance diagnosis in lateral flow and other immunoassay formats

New primary monoclonal antibodies · 16. April 2025

CCR10 Targeting with Monoclonal Antibodies: Unlocking New Frontiers in Immunology, Inflammation, and Oncology

SYnAbs unique R&D and therapeutic monoclonal antibodies to CCR10 (GPR-2), C-C chemokine Receptor 10 GPCR transmembrane protein

New primary monoclonal antibodies · 15. April 2025

The Added Value of Mouse and Rat Isotype Controls in Research

SYnAbs offers the complete portfolio of mouse and rat isotype controls IgG1, IgG2a, IgG2b, IgG2c, IgG3, IgA, IgE, IgM

New primary monoclonal antibodies · 10. April 2025

Valproic Acid: Clinical Relevance and the Role of Monoclonal Antibodies in Accurate Measurement

Valproic acid (VPA) is a widely used drug with narrow therapeutic window, necessitating precise monitoring of blood levels to avoid toxicity or sub-therapeutic effects. Traditional methods of measuring VPA have limitations in terms of sensitivity, specificity, and accuracy. In this context, SYnAbs has developed the best monoclonal antibodies against VPA.

New primary monoclonal antibodies · 18. March 2025

Androstenedione as a Diagnostic Marker: Clinical Significance and Immunological Challenges in Antibody Specificity

SYnAbs unique mouse and rat monoclonal antibodies to androstenedione without cross-reactivity to close analogs (DHEA,...)

New primary monoclonal antibodies · 02. October 2024

Understanding Radioimmunotherapy: A Breakthrough in Cancer Treatment

SYnAbs develops monoclonals to complex cancer epitopes to be used in theranostic oncology radioimmunotherapy treatments